A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck

Annals of Oncology

Volumn 11, Issue 5, 2000, Pages 535-539

  Colevas, A D ^a,b,d   Adak, S ^a   Amrein, P C ^c   Barton, J J ^a   Costello, R ^a   Posner, M R ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE   (United States)

Author keywords

5 FU; Docetaxel; Head and neck cancer; Phase II; Squamous cell carcinoma

Indexed keywords

DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEAD CANCER; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NECK CANCER; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PALLIATIVE CARE; TAXOIDS; TREATMENT OUTCOME;

EID: 0033933427     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008355413788     Document Type: Article

References (29)

1. Landis S, Murray T, Bolden S, Wingo P. Cancer statistics, 1998. CA Cancer J Clinicians 1998; 48: 6-30.
2. Schantz S, Sessions R, Harrison L et al. Cancer of the head and neck. In De Vita V, Hellman S, Rosenberg S (eds): Principles and Practices of Oncology. Philadelphia, Pennsylvania: Lippincott 1993; 574-672.
3. Pinto H, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin N Am 1991; 5: 667-86.
4. LHNOG. A phase III randomized trial of cisplatin, methotrexate, cisplatin + methotrexate and cisplatin + 5-FU in end stage squamous carcinoma of the head and neck. B J Cancer 1990; 61: 311-5.
5. Forastiere A, Metch B, Schuller D et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A southwest oncology group study. J Clin Oncol 1992; 10: 1245-51.
6. DeConti R, Schoenfeld D. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 1981; 48: 1061-72.
7. Jacobs C, Lyman G, Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous-cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-63.
8. Kish J, Weaver A, Jacobs J et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and desseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1819-24.
9. Kish J, Ensley J, Jacobs J et al. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol 1988; 11: 553-7.
10. Kish J, Ensley J, Jacobs J et al. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous-cell carcinoma of the head and neck. Cancer 1985; 56: 2740-4.
11. Catimel G, Verwij J, Hanauske A. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous-cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533-7.
12. Couteau C, Leyvraz S, Oulid-Aissa D et al. A phase II study of Docetaxel in squamous-cell carcinoma (SCC) of the head and neck. Proc Am Soc Clin Oncol 1996; 15: 315.
13. Dreyfuss A, Clark J, Norris C et al. Docetaxel: An active drug for squamous-cell carcinoma of the head and neck. J Clin Oncol 1996; 14: 1672-8.
14. Fujii H, Sasaki Y, Ebihara S et al. An early phase II study of docetaxel (Taxotere) in patients with head and neck cancer. Proc Am Soc Clin Oncol 1995 1995; 14: 298 (Abstr 859).
15. Smith R, Thornton D, Allen J. A phase II trial of paclitaxel in squamous-cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995; 22: 41-6.
16. Forastiere A, Shank D, Neuberg D et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous-cell carcinoma of the head and neck. Cancer 1998; 82: 2270-4.
17. Bissery M, Vrignaud P, Bayssas M, Lavelle F. Docetaxel (RP 56976, Taxotere) efficacy as a single agent or in combination against mammary tumors in mice. Proc Am Assoc Cancer Res 1994; 35: 327.
18. Bissery MC, Vrignaud P, Lavelle F. Preclinical profile of Docetaxel (Taxotere): Efficacy as a single agent and in combination. Semin Oncol 1995; 22: 3-16.
19. Peacock N, Rodriguez G, Smith L et al. A phase I study of docetaxel (Taxotere) and 5-FU combination chemotherapy in patients with advanced solid tumors. Proc ASCO 1996; 15: 490.
20. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - a phase II single-center study. J Clin Oncol 1999; 17: 1127-31.
21. Trudeau ME, Eisenhauer EA, Higgins BP et al. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
22. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer 1996; 74: 650-6.
23. Verweij J. Alexiera-Figresch J, De Boer M. Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. Eur J Cancer Clin Oncol 1998; 24: 795-6.
24. Forastiere A, Urba S. Single-agent paclitaxel and paxlitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 1995; 22: 24-7.
25. Vokes E, Athanasiadis I. Chemotherapy for squamous-cell carcinoma of head and neck: The future is now. Ann Oncol 1996; 7: 15-29.
26. Schoffski P, Catimel G, Planting A et al. Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent, or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 1999; 10: 119-22.
27. Clavel M, Vermorken J, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus csiplatin (C), in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC head and neck cancer cooperative group. Ann Onocol 1994; 5: 521-6.
28. Paredes J, Hong W, Felder T et al. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocabramate in recurrent and/or metastatic squamous-cell cancer of the head and neck. J Clin Oncol 1988; 6: 955-62.
29. Schrijvers D, Johnson J, Jimenez U et al. Phase III trial of modulation of cisplatin fluorouracil chemotherapy by interferon-α-2b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 1998; 16: 1054-9.